Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Serina Therapeutics, Inc.

SER ✓ COMPLIANTFree checks used up today ☆ Track — members

NYSE MKT · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$1.76

▼ -0.56%

Market Cap $44.70M · Vol 7.93K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$44.70M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

+17.28%

YoY

RSI (14)

36.84

Momentum

Beta

1.32

vs Market

52W High

$5.29

66.54% below

52W Low

$1.24

42.74% above

Volume

7.93K

Avg 7.43K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

49.24%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Serina Therapeutics, Inc. (SER) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SER pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.68%

-23.81%

-18.89%

-9.74%

YTD

-8.00%

-65.96%

-91.28%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$130.00K
Net Income	$-19,215,000.00
Revenue Growth (YoY)	-100.00%
Gross Margin	100.00%
Operating Margin	-18,478.46%
Net Profit Margin	-14,780.77%
ROE	N/A
ROA · ROIC	-280.76% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	149.95
P/B	N/A
P/FCF	N/A
EPS Growth	+17.28%
Outstanding Shares	25.40M

Technical Indicators

50-Day SMA	$2.27
200-Day SMA	$2.11
RSI (14)	36.84
Beta	1.32
52-Week High	$5.29
52-Week Low	$1.24

Volume Today	7.93K
Avg Daily Volume (30D)	7.43K
Relative Volume	1.07x
Volatility (10D)	64.70
Volatility (30D)	70.33
Free Float	49.24%

Analyst Consensus

STRONG BUY

Current Price $1.76

Mean Target $9.50

52W Low$1.24 52W High$5.29

Current

Target

$1.24 $5.29

Current Analyst target

+439.77% upside potential · 2 analysts

Identifiers

ExchangeNYSE MKT

FIGIBBG00HCXQ7C9

ISINUS81751A1088

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -6.02% ARGX.BR argenx SE -0.41% ARGX argenx SE -1.61% GMAB.CO Genmab A/S +1.30% GMAB Genmab A/S +1.09%

Company Profile

Serina Therapeutics Inc. is a clinical-stage biotechnology company developing a pipeline of wholly owned drug product candidates to treat neurological diseases and other indications. The Company's POZ Platform provides the potential to improve the integrated efficacy and safety profile of multiple modalities including small molecules, RNA-based therapeutics and antibody-based drug conjugates (ADCs). Its proprietary POZ technology is based on a synthetic, water soluble, low viscosity polymer called poly(2-oxazoline). Its POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection. SER-252 is the Company’s lead candidate for advanced Parkinson’s disease. SER-252 is an investigational apomorphine therapy developed with its POZ platform and designed to provide continuous dopaminergic stimulation.